Literature DB >> 8540610

Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications.

H L Ioachim1, S E Pambuccian, M Hekimgil, F R Giancotti, B H Dorsett.   

Abstract

In the course of investigating 30 monoclonal antibodies (MAbs) for their potential reactivity with 25 lung tumors of different histologic types, we found that three MAbs commonly used for their specificities for lymphoid markers were highly reactive with non-small-cell carcinomas (NSCLC) and totally nonreactive with small-cell carcinomas (SCLC). Immunostaining was performed by the standard streptavidin-biotin-peroxidase method after microwave antigen retrieval on formalin-fixed, paraffin-embedded tissue sections. LN2 (CD74), LN3 (HLA-DR), and BLA-36, which are commonly used for the identification of B-lymphocytes, strongly immunostained 19 of 25 squamous and adenocarcinomas and none of 34 small-cell carcinomas and carcinoids. Moreover, in combined tumors, these MAbs selectively stained the adenocarcinoma cells but not the adjacent small-cell carcinoma cells. A cocktail mixture of LN2, LN3, and BLA-36 assayed on 24 additional lung tumors produced similar results with even stronger and sharper stainings. Other lymphoid MAbs showed some selective staining but to a lesser degree. Among nonlymphoid MAbs, the results were as expected, with MAbs for cytokeratin (B72.3) and epithelial membrane antigen staining NSCLC but also some SCLC. The MAbs for chromogranin and neuron-specific enolase were not entirely specific, whereas some nerve-cell adhesion molecule MAbs showed good specificity for SCLC. In a field with few specific MAbs, the newly discovered ability of these lymphoid MAbs to discriminate between SCLC and NSCLC may prove useful in the immunohistochemical diagnosis of lung tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8540610     DOI: 10.1097/00000478-199601000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.

Authors:  Gaspar J Kitange; Brett L Carlson; Mark A Schroeder; Paul A Decker; Bruce W Morlan; Wenting Wu; Karla V Ballman; Caterina Giannini; Jann N Sarkaria
Journal:  J Neurooncol       Date:  2010-05-05       Impact factor: 4.130

2.  CD74 is a survival receptor on colon epithelial cells.

Authors:  Nitsan Maharshak; Sivan Cohen; Frida Lantner; Gili Hart; Lin Leng; Richard Bucala; Idit Shachar
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

3.  Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.

Authors:  David V Gold; Rhona Stein; Jack Burton; David M Goldenberg
Journal:  Int J Clin Exp Pathol       Date:  2010-11-23

4.  c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74.

Authors:  Maya Gordin; Melania Tesio; Sivan Cohen; Yael Gore; Frida Lantner; Lin Leng; Richard Bucala; Idit Shachar
Journal:  J Immunol       Date:  2010-07-16       Impact factor: 5.422

Review 5.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

6.  A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.

Authors:  Magdalena Pyrz; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

7.  Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer.

Authors:  Marc McClelland; Liujian Zhao; Shannon Carskadon; Douglas Arenberg
Journal:  Am J Pathol       Date:  2009-01-08       Impact factor: 4.307

8.  High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74-drug conjugate.

Authors:  Shuchun Zhao; Arturo Molina; Abigail Yu; Jeff Hanson; Harry Cheung; Xiaofan Li; Yasodha Natkunam
Journal:  J Pathol Clin Res       Date:  2018-10-08

9.  CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.

Authors:  Zuzana Berkova; Shu Wang; Xue Ao; Jillian F Wise; Frank K Braun; Abdol H Rezaeian; Lalit Sehgal; David M Goldenberg; Felipe Samaniego
Journal:  J Exp Clin Cancer Res       Date:  2014-10-10

10.  Expression of cluster of differentiation 74 in gallbladder carcinoma and the correlation with epithelial growth factor receptor levels.

Authors:  Peng Wang; Qiao Shi; Teng Zuo; Xiaobo He; Jia Yu; Weixing Wang
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.